Sutro Biopharma Inc.

NASDAQ: STRO · Real-Time Price · USD
0.83
-0.08 (-8.73%)
At close: Jun 05, 2025, 3:59 PM
0.81
-2.16%
After-hours: Jun 05, 2025, 07:57 PM EDT

Company Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.

It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.

It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology.

The company was formerly known as Fundamental Applied Biology, Inc.

Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma Inc.
Sutro Biopharma Inc. logo
Country United States
IPO Date Sep 27, 2018
Industry Biotechnology
Sector Healthcare
Employees 269
CEO Jane Chung R.Ph.

Contact Details

Address:
111 Oyster Point Boulevard
South San Francisco, California
United States
Website https://www.sutrobio.com

Stock Details

Ticker Symbol STRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001382101
CUSIP Number 869367102
ISIN Number US8693671021
Employer ID 45-2441988
SIC Code 2836

Key Executives

Name Position
Jane Chung R.Ph. Chief Executive Officer & Director
Edward C. Albini M.B.A Chief Financial Officer & Secretary
David Pauling J.D., M.A. Chief Administrative Officer & General Counsel
Dr. Barbara Leyman Ph.D. Chief Business Officer
Dr. Hans-Peter Gerber Ph.D. Chief Scientific Officer
Dr. James R. Swartz DSc, Ph.D., Sc.D. Founder
Dr. Venkatesh Srinivasan Ph.d. Chief Technical Operations Officer
Regina Cheng Vice President & Controller

Latest SEC Filings

Date Type Title
Jun 02, 2025 4 Filing
Jun 02, 2025 3 Filing
Jun 02, 2025 8-K Current Report
May 30, 2025 S-8 Filing
May 19, 2025 4 Filing
May 15, 2025 SCHEDULE 13G Filing
May 08, 2025 10-Q Quarterly Report
May 08, 2025 8-K Current Report
May 05, 2025 4 Filing
May 05, 2025 4 Filing